Immuneering CORP

Immuneering Corporation announces the appointment of Andrew Gengos as Chief Financial Officer and Treasurer, effective on or before July 16, 2026.

Immuneering Corporation successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of two directors and the appointment of its independent auditor.

Immuneering Corporation announced updated Phase 2a clinical trial results for atebimetinib in first-line pancreatic cancer, showing a 17.3-month median overall survival.

Immuneering Corporation announced first quarter 2026 financial results, highlighting progress in its atebimetinib clinical trials for pancreatic cancer and a cash runway extending into 2029.

Immuneering Corporation announced positive Phase 2a data for atebimetinib in pancreatic cancer, reporting 64% overall survival at 12 months, alongside full-year 2025 financial results and an extended cash runway into 2029.

Immuneering Corporation announced updated interim Phase 2a clinical trial data for atebimetinib in first-line pancreatic cancer, demonstrating significantly improved overall survival compared to standard of care.

Immuneering Corporation filed its Form 10-Q for the quarter ended March 31, 2026, detailing its financial performance, ongoing clinical trials, and strategic outlook.

Immuneering Corporation reported a significant increase in cash reserves to $227.6 million, extending its runway into 2029, and announced positive interim survival data for its lead pancreatic cancer drug candidate, atebimetinib.

Immuneering Corporation's Q2 2025 filing highlights promising interim clinical data for atebimetinib in pancreatic cancer, despite ongoing financial challenges and a going concern warning.

Immuneering Corporation's Q1 2025 results show continued losses and raise substantial doubt about its ability to continue as a going concern.

Immuneering Corporation's Q3 2024 report highlights ongoing clinical trials for IMM-1-104 and IMM-6-415, with a focus on financial stability and future funding needs.

Immuneering Corporation's second quarter 2024 results show a net loss of $14.1 million, with ongoing clinical trials for IMM-1-104 and IMM-6-415 progressing.

Immuneering Corporation reports positive interim Phase 2a data for atebimetinib in pancreatic cancer, initiating a Phase 3 trial, while pausing envometinib development to focus resources.

Immuneering Corporation's 2024 10-K filing reveals ongoing clinical trials, significant net losses, and substantial doubt about the company's ability to continue as a going concern.

Immuneering Corporation has disclosed changes to executive compensation, including salary increases, bonus adjustments, and new stock option grants, alongside new employment agreements for key personnel.

Andrew Gengos, Chief Financial Officer of Immuneering Corp, received 650,000 shares of common stock on July 16, 2026.

Immuneering Corp's President and CEO, Benjamin J. Zeskind, has acquired 2,400 shares of Class A Common Stock.

Director Thomas J. Schall was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Director Diana Hausman was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Director Robert J. Carpenter was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Director Laurie Keating was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Immuneering Corporation has issued its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 11, 2026.

Immuneering Corporation has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Immuneering Corporation will hold its annual meeting of stockholders virtually on June 13, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Immuneering Corporation has filed definitive additional materials related to its proxy statement with the SEC.

Immuneering Corporation will hold its annual meeting of stockholders virtually on June 12, 2024, to vote on the election of directors and ratification of the independent registered public accounting firm.

Benjamin J. Zeskind, a key insider at Immuneering Corporation, has reported beneficial ownership of 6.6% of the company's Class A common stock as of December 31, 2025.

Empery Asset Management and Ryan M. Lane report a 4.99% beneficial ownership stake in Immuneering Corp's Class A Common Stock, including warrants.

Empery Asset Management, LP and its managing members reported a beneficial ownership of 8.83% of Immuneering Corp.'s Class A Common Stock.

FMR LLC and Abigail P. Johnson disclose a 14.5% beneficial ownership in Immuneering Corp's Class A Common Stock as of September 30, 2025.

HBM Healthcare Investments (Cayman) Ltd. has reported a passive 5.7% beneficial ownership stake in Immuneering Corp, holding 3,646,304 shares of Class A Common Stock.

Benjamin J. Zeskind has filed an amended Schedule 13G, reporting a 12.8% beneficial ownership stake in Immuneering Corporation's Class A common stock as of December 31, 2024.